论文部分内容阅读
目的探讨联合雄激素阻断治疗晚期前列腺癌的疗效。方法选择38例晚期前列腺癌患者,明确诊断后口服Flutamid 250 mg,3次/d,3~7 d后腹部皮下注射LHRH-A 3.6mg,3个月后再行去势手术,术后继续服用Flutamid。分析38例去势加雄激素阻断剂治疗晚期前列腺癌的临床资料。结果化学去势加雄激素阻断治疗3个月可筛选排除雄激素非依赖性前列腺癌,其后的手术去势加雄激素阻断治疗可维持稳定的去势水平。本组复发4例,复发率10%,5例出现肝功能异常。结论联合雄激素阻断治疗晚期前列腺癌安全有效。
Objective To investigate the therapeutic effect of combined androgen blockade on advanced prostate cancer. Methods Thirty-eight patients with advanced prostate cancer were selected. Flutamid 250 mg orally and 3 times / d were given orally after diagnosis. LHRH-A 3.6 mg was injected subcutaneously in the abdomen 3 to 7 days after the diagnosis. After 3 months, castration surgery was continued. Flutamid. Clinical data of 38 cases of castrate androgen blocker in the treatment of advanced prostate cancer were analyzed. Results Chemoexploration and androgen blockade therapy can screen for androgen-independent prostate cancer after 3 months of treatment, followed by surgical castration and androgen blockade therapy can maintain a stable level of castration. 4 cases of recurrence in this group, the recurrence rate was 10%, 5 cases of liver dysfunction. Conclusions Combined androgen blockade is safe and effective in the treatment of advanced prostate cancer.